51239-46-4

Usage

Uses

Used in Pharmaceutical Industry:
4-(Aminomethyl)benzeneboronic acid is used as a key intermediate for the synthesis of various pharmaceuticals due to its ability to form carbon-carbon and carbon-nitrogen bonds, which are essential in the creation of complex drug molecules.
Used in Agrochemical Industry:
AMBC is utilized as a building block in the development of agrochemicals, contributing to the creation of effective compounds for pest control and crop protection.
Used in Materials Chemistry:
4-(Aminomethyl)benzeneboronic acid is employed as a component in the synthesis of advanced materials, leveraging its reactivity to form new materials with specific properties for various applications.
Used in Chemical Reactions:
AMBC is used as a reagent in chemical reactions for the formation of carbon-carbon and carbon-nitrogen bonds, which are crucial for the synthesis of a wide range of organic compounds.
Used in Treatment of Diabetes:
4-(Aminomethyl)benzeneboronic acid is used as a component in the development of treatments for diabetes, potentially aiding in the regulation of blood sugar levels and improving the management of the condition.
Used in Cancer Therapy:
AMBC is utilized in the research and development of cancer treatments, where it may contribute to the design of drugs that target specific cancer cells or pathways.
Used in Antibacterial Agents:
4-(Aminomethyl)benzeneboronic acid is used in the creation of antibacterial agents, potentially offering new solutions to combat bacterial infections and resistance.

Upstream product

• 489446-42-6 4-((tert-butoxycarbonylamino)methyl)phenylboronic acid 
• 126747-14-6 4-cyanophenylboronic acid 

Downstream Products

• 489446-42-6 4-((tert-butoxycarbonylamino)methyl)phenylboronic acid 
• 1239441-61-2 C₁₃H₁₁ClN₄ 
• 1415462-35-9 4-(3-oxazol-5-yl-2H-chromen-6-yl)-benzylamine 
• 138500-88-6 (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine 
• 1454653-73-6 N-benzyl-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine 
• 1454653-74-7 2-phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)ethanamine 
• 1454653-75-8 3-phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)propan-1-amine 

Relevant academic research and scientific papers

Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity

The mineralocorticoid receptor (MR) is a nuclear hormone receptor involved in the regulation of body fluid and electrolyte homeostasis. In this study we explore selectivity triggers for a series of nonsteroidal MR antagonists to improve selectivity over other members of the oxosteroid receptor family. A biaryl sulfonamide compound was identified in a high-throughput screening (HTS) campaign. The compound bound to MR with pKi=6.6, but displayed poor selectivity over the glucocorticoid receptor (GR) and the progesterone receptor (PR). Following X-ray crystallography of MR in complex with the HTS hit, a compound library was designed that explored an induced-fit hypothesis that required movement of the Met852 side chain. An improvement in MR selectivity of 11- to 79-fold over PR and 23- to 234-fold over GR was obtained. Given the U-shaped binding conformation, macrocyclizations were explored, yielding a macrocycle that bound to MR with pKi=7.3. Two protein–ligand X-ray structures were determined, confirming the hypothesized binding mode for the designed compounds.

BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION

Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. in vivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding domains on a protein or on different proteins.